Eylea is not a steroid. It belongs to a completely different class of medications called VEGF inhibitors (sometimes written as “anti-VEGF” drugs). While both Eylea and steroid eye treatments can reduce swelling in the retina, they work through entirely different biological mechanisms and carry different risk profiles.
What Eylea Actually Is
Eylea’s active ingredient, aflibercept, is a lab-made protein designed to intercept a specific chemical signal in your body called vascular endothelial growth factor, or VEGF. VEGF tells your body to grow new blood vessels and makes existing blood vessels leaky. In several eye diseases, too much VEGF causes abnormal blood vessel growth and fluid buildup in the retina, which damages vision.
Aflibercept works like a decoy receptor. It binds to VEGF molecules floating in the eye and neutralizes them before they can attach to your blood vessels. This stops the chain reaction that leads to leaky vessels and retinal swelling. Eylea also blocks a related signal called placental growth factor (PlGF), giving it a dual effect that some other anti-VEGF drugs don’t have.
Steroids, by contrast, are broad anti-inflammatory drugs. They suppress a wide range of immune and inflammatory pathways in the body. When injected into the eye, steroids reduce swelling by dampening overall inflammation rather than targeting one specific growth signal.
Conditions Eylea Treats
The FDA has approved Eylea for five retinal conditions:
- Wet age-related macular degeneration (AMD), where abnormal blood vessels grow beneath the retina
- Diabetic macular edema (DME), swelling in the center of the retina caused by diabetes
- Diabetic retinopathy, broader blood vessel damage from diabetes
- Macular edema following retinal vein occlusion, swelling after a blood vessel blockage in the retina
- Retinopathy of prematurity, abnormal blood vessel growth in premature infants
A higher-dose version called Eylea HD (8 mg) is approved for wet AMD, DME, and diabetic retinopathy, and may allow longer intervals between injections for some patients.
How Well Eylea Works
In clinical trials for diabetic macular edema, patients receiving Eylea gained an average of about 11 letters on a standard eye chart after two years. That’s roughly two lines of improved reading ability. Patients in the comparison group who received laser treatment gained less than one letter over the same period. These gains held whether patients received injections monthly or every two months after an initial loading phase.
Why People Confuse Eylea With Steroids
The confusion is understandable. Both Eylea and steroid implants are injected directly into the eye, both treat retinal swelling, and both are used for overlapping conditions like diabetic macular edema and vein occlusion. If your doctor mentions an eye injection for macular edema, it could be either type of treatment.
Adding to the confusion, Eylea can cause some side effects that people associate with steroids, including increased eye pressure and cataracts. With Eylea, pressure spikes typically happen within 60 minutes of the injection and resolve on their own. Cataracts were reported as a common side effect in clinical trials, though the mechanism differs from steroid-induced cataracts. Steroid eye treatments cause pressure elevation and cataracts far more frequently, and these side effects tend to be more persistent.
When Steroids Are Used Instead
Actual steroid treatments for the eye do exist and are sometimes used for the same conditions Eylea treats. Implants containing dexamethasone or fluocinolone acetonide are placed inside the eye and release medication slowly over weeks or months. These are genuine corticosteroids.
Eye specialists typically reach for steroids in a few specific situations. If a patient’s macular edema doesn’t improve after three or four anti-VEGF injections, the swelling may be driven more by inflammation than by VEGF, making a steroid a better fit. Patients who’ve already had cataract surgery (and therefore can’t develop new cataracts) are sometimes switched to steroids earlier, since one of the main drawbacks no longer applies. Steroids also make sense for patients who can’t keep up with the frequent injection schedule that anti-VEGF drugs require, since steroid implants can last longer between treatments.
In some cases, doctors combine an anti-VEGF drug like Eylea with a steroid implant to address both the VEGF-driven leakage and the inflammatory component at the same time.
Key Differences at a Glance
- Drug class: Eylea is a VEGF inhibitor. Steroid eye treatments (like dexamethasone implants) are corticosteroids.
- How they work: Eylea blocks a single growth factor that drives abnormal blood vessel behavior. Steroids suppress broad inflammatory pathways.
- Injection frequency: Eylea is given every 4 to 12 weeks depending on the condition and formulation. Steroid implants can last several months per treatment.
- Pressure and cataract risk: Both can raise eye pressure, but the risk is substantially higher and longer-lasting with steroids. The same is true for cataracts.